HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy

High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates

(2015) I. Bonzheim et al.   BLOOD

The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy

(2015) S. Walz et al.   BLOOD

MYD88L265P andCXCR4mutations in lymphoplasmacytic lymphoma identify cases with high disease activity

(2015) Janine Schmidt et al.   BRITISH JOURNAL OF HAEMATOLOGY

Targeting immune checkpoints in lymphoma

(2015) Stephen M. Ansell   CURRENT OPINION IN HEMATOLOGY

Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas

(2015) Peter Martin et al.   LEUKEMIA & LYMPHOMA

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

(2015) Wyndham H Wilson et al.   NATURE MEDICINE

NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma

(2015) Aaron P Rapoport et al.   NATURE MEDICINE

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

(2015) Stephen M. Ansell et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy

(2015) Janet Kerstin Peper et al.   OncoImmunology

Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization

(2014) M. Avbelj et al.   BLOOD

Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome

(2014) A. Martinez-Trillos et al.   BLOOD

Orchestrating immune check-point blockade for cancer immunotherapy in combinations

(2014) Jose Luis Perez-Gracia et al.   CURRENT OPINION IN IMMUNOLOGY

Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity

(2014) Fei Duan et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy

(2014) C Berlin et al.   LEUKEMIA

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

(2014) Alexandra Snyder et al.   NEW ENGLAND JOURNAL OF MEDICINE

HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)

(2014) Daniel J. Kowalewski et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma

(2014) S M Ansell et al.   Blood Cancer Journal

Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms

(2013) M. Varettoni et al.   BLOOD

Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)

(2013) J. Greiner et al.   BLOOD

MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction

(2013) L. Xu et al.   BLOOD

Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer

(2013) Anneke Neumann et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia

(2013) Dan A. Landau et al.   CELL

Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma

(2013) Nienke van Rooij et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia

(2012) J. Greiner et al.   BLOOD

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia

(2012) Steven P. Treon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients

(2011) Melanie Widenmeyer et al.   INTERNATIONAL JOURNAL OF CANCER

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

(2011) Xose S. Puente et al.   NATURE

Analysis of the coding genome of diffuse large B-cell lymphoma

(2011) Laura Pasqualucci et al.   NATURE GENETICS

A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function

(2010) Jonas Stanke et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options

(2010) Apostolia-Maria Tsimberidou et al.   LEUKEMIA & LYMPHOMA

Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients

(2010) Susanne M Rittig et al.   MOLECULAR THERAPY

Oncogenically active MYD88 mutations in human lymphoma

(2010) Vu N. Ngo et al.   NATURE

Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers

(2008) C. Lundegaard et al.   BIOINFORMATICS

Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials

(2008) Hyun Jun Park et al.   BRITISH JOURNAL OF HAEMATOLOGY

Stromal Gene Signatures in Large-B-Cell Lymphomas

(2008) G. Lenz et al.   NEW ENGLAND JOURNAL OF MEDICINE

NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11

(2008) Claus Lundegaard et al.   NUCLEIC ACIDS RESEARCH